<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32692176</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-4804</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <Issue>22</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medicinal chemistry</Title>
          <ISOAbbreviation>J Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?</ArticleTitle>
        <Pagination>
          <StartPage>13258</StartPage>
          <EndPage>13265</EndPage>
          <MedlinePgn>13258-13265</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">acs.jmedchem.0c00776</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.0c00776</ELocationID>
        <Abstract>
          <AbstractText>Cathepsin C (CatC) is a cysteine dipeptidyl aminopeptidase that activates most of tissue-degrading elastase-related serine proteases. Thus, CatC appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory and autoimmune diseases. A depletion of proinflammatory elastase-related proteases in neutrophils is observed in patients with CatC deficiency (Papillon-Lefèvre syndrome). To address and counterbalance unwanted effects of elastase-related proteases, chemical inhibitors of CatC are being evaluated in preclinical and clinical trials. Neutrophils may contribute to the diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently a growing challenge for intensive care units due to the outbreak of the COVID-19 pandemic. Elimination of elastase-related neutrophil proteases may reduce the progression of lung injury in these patients. Pharmacological CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Korkmaz</LastName>
            <ForeName>Brice</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-5159-8706</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR-1100, Centre d'Etude des Pathologies Respiratoires and Université de Tours, 37032 Tours, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lesner</LastName>
            <ForeName>Adam</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-8335-3431</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Chemistry, University of Gdansk, 80-398 Gdansk, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchand-Adam</LastName>
            <ForeName>Sylvain</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9522-3738</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR-1100, Centre d'Etude des Pathologies Respiratoires and Université de Tours, 37032 Tours, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Service de Pneumologie, CHRU de Tours, 37032 Tours, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moss</LastName>
            <ForeName>Celia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Children's Hospital and University of Birmingham, B4 6NH Birmingham, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jenne</LastName>
            <ForeName>Dieter E</ForeName>
            <Initials>DE</Initials>
            <Identifier Source="ORCID">0000-0002-1125-9144</Identifier>
            <AffiliationInfo>
              <Affiliation>Comprehensive Pneumology Center, Institute of Lung Biology and Disease, German Center for Lung Research (DZL), Munich and Max-Planck Institute of Neurobiology, 82152 Planegg-Martinsried, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Chem</MedlineTA>
        <NlmUniqueID>9716531</NlmUniqueID>
        <ISSNLinking>0022-2623</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.14.1</RegistryNumber>
          <NameOfSubstance UI="D020789">Cathepsin C</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020789" MajorTopicYN="N">Cathepsin C</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020556" MajorTopicYN="N">Neutrophil Infiltration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare the following competing financial interest(s): Brice
Korkmaz has been paid for the time spent as a committee member for advisory
boards, other forms of consulting, symposium organization, and lectures or
presentations. These payments were made directly to the University of Tours,
and no personal payments were received in relation to these activities. All
other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32692176</ArticleId>
        <ArticleId IdType="pmc">PMC7413214</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jmedchem.0c00776</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Yang X.; Yu Y.; Xu J.; Shu H.; Xia J.; Liu H.; Wu Y.; Zhang L.; Yu Z.; Fang M.; Yu T.; Wang Y.; Pan S.; Zou X.; Yuan S.; Shang Y.
Clinical course and outcomes of critically ill patients
with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
retrospective, observational study. Lancet Respir. Med.
2020, 8, 475–481. 10.1016/S2213-2600(20)30079-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId>
            <ArticleId IdType="pmc">PMC7102538</ArticleId>
            <ArticleId IdType="pubmed">32105632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagunas-Rangel F. A.
Neutrophil-to-lymphocyte ratio and
lymphocyte-to-C-reactive protein ratio in patients with severe
coronavirus disease 2019 (COVID-19): a
meta-analysis. J. Med. Virol.
2020, 10.1002/jmv.25819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.25819</ArticleId>
            <ArticleId IdType="pmc">PMC7228336</ArticleId>
            <ArticleId IdType="pubmed">32242950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlman S.; Dandekar A. A.
Immunopathogenesis of coronavirus infections:
implications for SARS. Nat. Rev. Immunol.
2005, 5, 917–927. 10.1038/nri1732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1732</ArticleId>
            <ArticleId IdType="pmc">PMC7097326</ArticleId>
            <ArticleId IdType="pubmed">16322745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P.; Summer W. R.; Bagby G. J.; Nelson S.
Innate immunity and pulmonary host
defense. Immunol. Rev.
2000, 173, 39–51. 10.1034/j.1600-065X.2000.917306.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-065X.2000.917306.x</ArticleId>
            <ArticleId IdType="pubmed">10719666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yipp B. G.; Kim J. H.; Lima R.; Zbytnuik L. D.; Petri B.; Swanlund N.; Ho M.; Szeto V. G.; Tak T.; Koenderman L.; Pickkers P.; Tool A. T. J.; Kuijpers T. W.; van den Berg T. K.; Looney M. R.; Krummel M. F.; Kubes P.
The lung is a host defense niche for immediate
neutrophil-mediated vascular protection. Sci. Immunol
2017, 2, eaam8929.10.1126/sciimmunol.aam8929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aam8929</ArticleId>
            <ArticleId IdType="pmc">PMC5472445</ArticleId>
            <ArticleId IdType="pubmed">28626833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkmaz B.; Caughey G. H.; Chapple I.; Gauthier F.; Hirschfeld J.; Jenne D. E.; Kettritz R.; Lalmanach G.; Lamort A. S.; Lauritzen C.; Legowska M.; Lesner A.; Marchand-Adam S.; McKaig S. J.; Moss C.; Pedersen J.; Roberts H.; Schreiber A.; Seren S.; Thakker N. S.
Therapeutic targeting of cathepsin C: from
pathophysiology to treatment. Pharmacol. Ther.
2018, 190, 202–236. 10.1016/j.pharmthera.2018.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2018.05.011</ArticleId>
            <ArticleId IdType="pubmed">29842917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkmaz B.; Horwitz M.; Jenne D. E.; Gauthier F.
Neutrophil elastase, proteinase 3 and cathepsin G as
therapeutic targets in human diseases. Pharmacol. Rev.
2010, 62, 726–759. 10.1124/pr.110.002733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.110.002733</ArticleId>
            <ArticleId IdType="pmc">PMC2993259</ArticleId>
            <ArticleId IdType="pubmed">21079042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raptis S. Z.; Shapiro S. D.; Simmons P. M.; Cheng A. M.; Pham C. T.
Serine protease cathepsin G regulates
adhesion-dependent neutrophil effector functions by modulating
integrin clustering. Immunity
2005, 22, 679–691. 10.1016/j.immuni.2005.03.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2005.03.015</ArticleId>
            <ArticleId IdType="pubmed">15963783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehm S. R. T.; Smirnova N. F.; Morrone C.; Gotzfried J.; Feuchtinger A.; Pedersen J.; Korkmaz B.; Yildirim A. O.; Jenne D. E.
Premedication with a cathepsin C inhibitor alleviates
early primary graft dysfunction in mouse recipients after lung
transplantation. Sci. Rep.
2019, 9, 9925.10.1038/s41598-019-46206-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-46206-8</ArticleId>
            <ArticleId IdType="pmc">PMC6616352</ArticleId>
            <ArticleId IdType="pubmed">31289357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papayannopoulos V.; Metzler K. D.; Hakkim A.; Zychlinsky A.
Neutrophil elastase and myeloperoxidase regulate the
formation of neutrophil extracellular traps. J. Cell Biol.
2010, 191, 677–691. 10.1083/jcb.201006052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201006052</ArticleId>
            <ArticleId IdType="pmc">PMC3003309</ArticleId>
            <ArticleId IdType="pubmed">20974816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes B. J.; Adrover J. M.; Baxter-Stoltzfus A.; Borczuk A.; Cools-Lartigue J.; Crawford J. M.; Dassler-Plenker J.; Guerci P.; Huynh C.; Knight J. S.; Loda M.; Looney M. R.; McAllister F.; Rayes R.; Renaud S.; Rousseau S.; Salvatore S.; Schwartz R. E.; Spicer J. D.; Yost C. C.; Weber A.; Zuo Y.; Egeblad M.
Targeting potential drivers of COVID-19: neutrophil
extracellular traps. J. Exp. Med.
2020, 217, 217.10.1084/jem.20200652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20200652</ArticleId>
            <ArticleId IdType="pmc">PMC7161085</ArticleId>
            <ArticleId IdType="pubmed">32302401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuo Y.; Yalavarthi S.; Shi H.; Gockman K.; Zuo M.; Madison J. A.; Blair C. N.; Weber A.; Barnes B. J.; Egeblad M.; Woods R. J.; Kanthi Y.; Knight J. S.
Neutrophil extracellular traps in
COVID-19. JCI Insight
2020, 5.10.1172/jci.insight.138999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId>
            <ArticleId IdType="pmc">PMC7308057</ArticleId>
            <ArticleId IdType="pubmed">32329756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikacenic C.; Moore R.; Dmyterko V.; West T. E.; Altemeier W. A.; Liles W. C.; Lood C.
Neutrophil extracellular traps (NETs) are increased in
the alveolar spaces of patients with ventilator-associated
pneumonia. Crit Care
2018, 22, 358.10.1186/s13054-018-2290-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13054-018-2290-8</ArticleId>
            <ArticleId IdType="pmc">PMC6307268</ArticleId>
            <ArticleId IdType="pubmed">30587204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mozzini C.; Girelli D.
The role of Neutrophil Extracellular Traps in Covid-19:
Only an hypothesis or a potential new field of
research?. Thromb. Res.
2020, 191, 26–27. 10.1016/j.thromres.2020.04.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2020.04.031</ArticleId>
            <ArticleId IdType="pmc">PMC7184981</ArticleId>
            <ArticleId IdType="pubmed">32360977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkmaz B.; Kellenberger C.; Viaud-Massuard M. C.; Gauthier F.
Selective inhibitors of human neutrophil proteinase
3. Curr. Pharm. Des.
2013, 19, 966–976. 10.2174/1381612811319060002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612811319060002</ArticleId>
            <ArticleId IdType="pubmed">23016687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkmaz B.; Lesner A.; Guarino C.; Wysocka M.; Kellenberger C.; Watier H.; Specks U.; Gauthier F.; Jenne D. E.
Inhibitors and antibody fragments as potential
anti-inflammatory therapeutics targeting neutrophil proteinase 3
in human disease. Pharmacol. Rev.
2016, 68, 603–630. 10.1124/pr.115.012104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.115.012104</ArticleId>
            <ArticleId IdType="pubmed">27329045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawabata K.; Hagio T.; Matsuoka S.
Pharmacological profile of a specific neutrophil
elastase inhibitor, Sivelestat sodium hydrate. Nippon Yakurigaku Zasshi
2003, 122, 151–160. 10.1254/fpj.122.151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1254/fpj.122.151</ArticleId>
            <ArticleId IdType="pubmed">12890901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawabata K.; Suzuki M.; Sugitani M.; Imaki K.; Toda M.; Miyamoto T.
ONO-5046, a novel inhibitor of human neutrophil
elastase. Biochem. Biophys. Res. Commun.
1991, 177, 814–820. 10.1016/0006-291X(91)91862-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-291X(91)91862-7</ArticleId>
            <ArticleId IdType="pubmed">2049103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeiher B. G.; Artigas A.; Vincent J. L.; Dmitrienko A.; Jackson K.; Thompson B. T.; Bernard G.
Neutrophil elastase inhibition in acute lung injury:
results of the STRIVE study. Crit. Care Med.
2004, 32, 1695–1702. 10.1097/01.CCM.0000133332.48386.85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.CCM.0000133332.48386.85</ArticleId>
            <ArticleId IdType="pubmed">15286546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turk D.; Janjic V.; Stern I.; Podobnik M.; Lamba D.; Dahl S. W.; Lauritzen C.; Pedersen J.; Turk V.; Turk B.
Structure of human dipeptidyl peptidase I (cathepsin
C): exclusion domain added to an endopeptidase framework creates
the machine for activation of granular serine
proteases. EMBO J.
2001, 20, 6570–6582. 10.1093/emboj/20.23.6570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/20.23.6570</ArticleId>
            <ArticleId IdType="pmc">PMC125750</ArticleId>
            <ArticleId IdType="pubmed">11726493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahl S. W.; Halkier T.; Lauritzen C.; Dolenc I.; Pedersen J.; Turk V.; Turk B.
Human recombinant pro-dipeptidyl peptidase I (cathepsin
C) can be activated by cathepsins L and S but not by
autocatalytic processing. Biochemistry
2001, 40, 1671–1678. 10.1021/bi001693z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi001693z</ArticleId>
            <ArticleId IdType="pubmed">11327826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamort A. S.; Hamon Y.; Czaplewski C.; Gieldon A.; Seren S.; Coquet L.; Lecaille F.; Lesner A.; Lalmanach G.; Gauthier F.; Jenne D.; Korkmaz B.
Processing and maturation of cathepsin C zymogen: a
biochemical and molecular modeling analysis. Int. J. Mol. Sci.
2019, 20, 4747.10.3390/ijms20194747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20194747</ArticleId>
            <ArticleId IdType="pmc">PMC6801622</ArticleId>
            <ArticleId IdType="pubmed">31557781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schechter I.; Berger A.
On the size of the active site in proteases. I.
Papain. Biochem. Biophys. Res. Commun.
1967, 27, 157–162. 10.1016/S0006-291X(67)80055-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-291X(67)80055-X</ArticleId>
            <ArticleId IdType="pubmed">6035483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adkison A. M.; Raptis S. Z.; Kelley D. G.; Pham C. T.
Dipeptidyl peptidase I activates neutrophil-derived
serine proteases and regulates the development of acute
experimental arthritis. J. Clin. Invest.
2002, 109, 363–371. 10.1172/JCI0213462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI0213462</ArticleId>
            <ArticleId IdType="pmc">PMC150852</ArticleId>
            <ArticleId IdType="pubmed">11827996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham C. T.; Ivanovich J. L.; Raptis S. Z.; Zehnbauer B.; Ley T. J.
Papillon-Lefevre syndrome: correlating the molecular,
cellular, and clinical consequences of cathepsin C/dipeptidyl
peptidase I deficiency in humans. J. Immunol.
2004, 173, 7277–7281. 10.4049/jimmunol.173.12.7277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.173.12.7277</ArticleId>
            <ArticleId IdType="pubmed">15585850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toomes C.; James J.; Wood A. J.; Wu C. L.; McCormick D.; Lench N.; Hewitt C.; Moynihan L.; Roberts E.; Woods C. G.; Markham A.; Wong M.; Widmer R.; Ghaffar K. A.; Pemberton M.; Hussein I. R.; Temtamy S. A.; Davies R.; Read A. P.; Sloan P.; Dixon M. J.; Thakker N. S.
Loss-of-function mutations in the cathepsin C gene
result in periodontal disease and palmoplantar
keratosis. Nat. Genet.
1999, 23, 421–424. 10.1038/70525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/70525</ArticleId>
            <ArticleId IdType="pubmed">10581027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart T. C.; Hart P. S.; Michalec M. D.; Zhang Y.; Firatli E.; Van Dyke T. E.; Stabholz A.; Zlotogorski A.; Shapira L.; Soskolne W. A.
Haim-Munk syndrome and Papillon-Lefèvre syndrome
are allelic mutations in cathepsin C. J. Med. Genet
2000, 37, 88–94. 10.1136/jmg.37.2.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.37.2.88</ArticleId>
            <ArticleId IdType="pmc">PMC1734521</ArticleId>
            <ArticleId IdType="pubmed">10662807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perera N. C.; Wiesmuller K. H.; Larsen M. T.; Schacher B.; Eickholz P.; Borregaard N.; Jenne D. E.
NSP4 is stored in azurophil granules and released by
activated neutrophils as active endoprotease with restricted
specificity. J. Immunol.
2013, 191, 2700–2707. 10.4049/jimmunol.1301293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1301293</ArticleId>
            <ArticleId IdType="pubmed">23904161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seren S.; Rashed Abouzaid M.; Eulenberg-Gustavus C.; Hirschfeld J.; Nasr Soliman H.; Jerke U.; N’Guessan K.; Dallet-Choisy S.; Lesner A.; Lauritzen C.; Schacher B.; Eickholz P.; Nagy N.; Szell M.; Croix C.; Viaud-Massuard M. C.; Al Farraj Aldosari A.; Ragunatha S.; Ibrahim Mostafa M.; Giampieri F.; Battino M.; Cornillier H.; Lorette G.; Stephan J. L.; Goizet C.; Pedersen J.; Gauthier F.; Jenne D. E.; Marchand-Adam S.; Chapple I. L.; Kettritz R.; Korkmaz B.
Consequences of cathepsin C inactivation for membrane
exposure of proteinase 3, the target antigen in autoimmune
vasculitis. J. Biol. Chem.
2018, 293, 12415–12428. 10.1074/jbc.RA118.001922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.001922</ArticleId>
            <ArticleId IdType="pmc">PMC6093229</ArticleId>
            <ArticleId IdType="pubmed">29925593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorensen O. E.; Clemmensen S. N.; Dahl S. L.; Ostergaard O.; Heegaard N. H.; Glenthoj A.; Nielsen F. C.; Borregaard N.
Papillon-Lefèvre syndrome patient reveals
species-dependent requirements for neutrophil
defenses. J. Clin. Invest.
2014, 124, 4539–4548. 10.1172/JCI76009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI76009</ArticleId>
            <ArticleId IdType="pmc">PMC4191054</ArticleId>
            <ArticleId IdType="pubmed">25244098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts H.; White P.; Dias I.; McKaig S.; Veeramachaneni R.; Thakker N.; Grant M.; Chapple I.
Characterization of neutrophil function in
Papillon-Lefèvre syndrome. J. Leukocyte Biol.
2016, 100, 433–444. 10.1189/jlb.5A1015-489R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.5A1015-489R</ArticleId>
            <ArticleId IdType="pubmed">26957212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkmaz B.; Lesner A.; Wysocka M.; Gieldon A.; Hakansson M.; Gauthier F.; Logan D. T.; Jenne D. E.; Lauritzen C.; Pedersen J.
Structure-based design and in vivo anti-arthritic
activity evaluation of a potent dipeptidyl cyclopropyl nitrile
inhibitor of cathepsin C. Biochem. Pharmacol.
2019, 164, 349–367. 10.1016/j.bcp.2019.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2019.04.006</ArticleId>
            <ArticleId IdType="pubmed">30978322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guay D.; Beaulieu C.; Jagadeeswar Reddy T.; Zamboni R.; Methot N.; Rubin J.; Ethier D.; David Percival M.
Design and synthesis of dipeptidyl nitriles as potent,
selective, and reversible inhibitors of cathepsin
C. Bioorg. Med. Chem. Lett.
2009, 19, 5392–5396. 10.1016/j.bmcl.2009.07.114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2009.07.114</ArticleId>
            <ArticleId IdType="pubmed">19665376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furber M.; Tiden A. K.; Gardiner P.; Mete A.; Ford R.; Millichip I.; Stein L.; Mather A.; Kinchin E.; Luckhurst C.; Barber S.; Cage P.; Sanganee H.; Austin R.; Chohan K.; Beri R.; Thong B.; Wallace A.; Oreffo V.; Hutchinson R.; Harper S.; Debreczeni J.; Breed J.; Wissler L.; Edman K.
Cathepsin C inhibitors: property optimization and
identification of a clinical candidate. J. Med. Chem.
2014, 57, 2357–2367. 10.1021/jm401705g.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm401705g</ArticleId>
            <ArticleId IdType="pubmed">24592859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laine D. I.; Busch-Petersen J.
Inhibitors of cathepsin C (dipeptidyl peptidase
I). Expert Opin. Ther. Pat.
2010, 20, 497–506. 10.1517/13543771003657172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543771003657172</ArticleId>
            <ArticleId IdType="pubmed">20205619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laine D.; Palovich M.; McCleland B.; Petitjean E.; Delhom I.; Xie H.; Deng J.; Lin G.; Davis R.; Jolit A.; Nevins N.; Zhao B.; Villa J.; Schneck J.; McDevitt P.; Midgett R.; Kmett C.; Umbrecht S.; Peck B.; Davis A. B.; Bettoun D.
Discovery of novel cyanamide-based inhibitors of
cathepsin C. ACS Med. Chem. Lett.
2011, 2, 142–147. 10.1021/ml100212k.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml100212k</ArticleId>
            <ArticleId IdType="pmc">PMC4018094</ArticleId>
            <ArticleId IdType="pubmed">24900293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bondebjerg J.; Fuglsang H.; Valeur K. R.; Pedersen J.; Naerum L.
Dipeptidyl nitriles as human dipeptidyl peptidase I
inhibitors. Bioorg. Med. Chem. Lett.
2006, 16, 3614–3617. 10.1016/j.bmcl.2006.01.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2006.01.102</ArticleId>
            <ArticleId IdType="pubmed">16647256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kack H.; Doyle K.; Hughes S. J.; Bodnarchuk M. S.; Lonn H.; Van De Poel A.; Palmer N.
DPP1 inhibitors: exploring the role of water in the S2
pocket of DPP1 with substituted pyrrolidines. ACS Med. Chem. Lett.
2019, 10, 1222–1227. 10.1021/acsmedchemlett.9b00261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.9b00261</ArticleId>
            <ArticleId IdType="pmc">PMC6691682</ArticleId>
            <ArticleId IdType="pubmed">31413809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molgaard A.; Arnau J.; Lauritzen C.; Larsen S.; Petersen G.; Pedersen J.
The crystal structure of human dipeptidyl peptidase I
(cathepsin C) in complex with the inhibitor
Gly-Phe-CHN2. Biochem. J.
2007, 401, 645–650. 10.1042/BJ20061389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20061389</ArticleId>
            <ArticleId IdType="pmc">PMC1770842</ArticleId>
            <ArticleId IdType="pubmed">17020538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran T. V.; Ellis K. A.; Kam C. M.; Hudig D.; Powers J. C.
Dipeptidyl peptidase I: importance of progranzyme
activation sequences, other dipeptide sequences, and the
N-terminal amino group of synthetic substrates for enzyme
activity. Arch. Biochem. Biophys.
2002, 403, 160–170. 10.1016/S0003-9861(02)00217-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0003-9861(02)00217-5</ArticleId>
            <ArticleId IdType="pubmed">12139965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Methot N.; Guay D.; Rubin J.; Ethier D.; Ortega K.; Wong S.; Normandin D.; Beaulieu C.; Reddy T. J.; Riendeau D.; Percival M. D.
In vivo inhibition of serine protease processing
requires a high fractional inhibition of cathepsin
C. Mol. Pharmacol.
2008, 73, 1857–1865. 10.1124/mol.108.045682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.108.045682</ArticleId>
            <ArticleId IdType="pubmed">18326050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Methot N.; Rubin J.; Guay D.; Beaulieu C.; Ethier D.; Reddy T. J.; Riendeau D.; Percival M. D.
Inhibition of the activation of multiple serine
proteases with a cathepsin C inhibitor requires sustained
exposure to prevent pro-enzyme processing. J. Biol. Chem.
2007, 282, 20836–20846. 10.1074/jbc.M702615200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M702615200</ArticleId>
            <ArticleId IdType="pubmed">17535802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle K.; Lonn H.; Kack H.; Van de Poel A.; Swallow S.; Gardiner P.; Connolly S.; Root J.; Wikell C.; Dahl G.; Stenvall K.; Johannesson P.
Discovery of second generation reversible covalent DPP1
inhibitors leading to an oxazepane amidoacetonitrile based
clinical candidate (AZD7986). J. Med. Chem.
2016, 59, 9457–9472. 10.1021/acs.jmedchem.6b01127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b01127</ArticleId>
            <ArticleId IdType="pubmed">27690432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamon Y.; Legowska M.; Herve V.; Dallet-Choisy S.; Marchand-Adam S.; Vanderlynden L.; Demonte M.; Williams R.; Scott C. J.; Si-Tahar M.; Heuze-Vourc’h N.; Lalmanach G.; Jenne D. E.; Lesner A.; Gauthier F.; Korkmaz B.
Neutrophilic cathepsin C is maturated by a multi-step
proteolytic process and secreted by activated cells during
inflammatory lung diseases. J. Biol. Chem.
2016, 291, 8486–8499. 10.1074/jbc.M115.707109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M115.707109</ArticleId>
            <ArticleId IdType="pmc">PMC4861422</ArticleId>
            <ArticleId IdType="pubmed">26884336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guarino C.; Hamon Y.; Croix C.; Lamort A. S.; Dallet-Choisy S.; Marchand-Adam S.; Lesner A.; Baranek T.; Viaud-Massuard M. C.; Lauritzen C.; Pedersen J.; Heuze-Vourc’h N.; Si-Tahar M.; Firatli E.; Jenne D. E.; Gauthier F.; Horwitz M. S.; Borregaard N.; Korkmaz B.
Prolonged pharmacological inhibition of cathepsin C
results in elimination of neutrophil serine
proteases. Biochem. Pharmacol.
2017, 131, 52–67. 10.1016/j.bcp.2017.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2017.02.009</ArticleId>
            <ArticleId IdType="pubmed">28193451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer R.; Maenpaa J.; Jauhiainen A.; Larsson B.; Mo J.; Russell M.; Root J.; Prothon S.; Chialda L.; Forte P.; Egelrud T.; Stenvall K.; Gardiner P.
Dipeptidyl peptidase 1 inhibitor AZD7986 induces a
sustained, exposure-dependent reduction in neutrophil elastase
activity in healthy subjects. Clin. Pharmacol. Ther.
2018, 104, 1155–1164. 10.1002/cpt.1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpt.1053</ArticleId>
            <ArticleId IdType="pmc">PMC6282495</ArticleId>
            <ArticleId IdType="pubmed">29484635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T.; Luo S.; Libby P.; Shi G. P.
Cathepsin L-selective inhibitors: a potentially
promising treatment for COVID-19 patients. Pharmacol. Ther.
2020, 213, 107587.10.1016/j.pharmthera.2020.107587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2020.107587</ArticleId>
            <ArticleId IdType="pmc">PMC7255230</ArticleId>
            <ArticleId IdType="pubmed">32470470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kruger N.; Herrler T.; Erichsen S.; Schiergens T. S.; Herrler G.; Wu N. H.; Nitsche A.; Muller M. A.; Drosten C.; Pohlmann S.
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease
inhibitor. Cell
2020, 181, 271–280. 10.1016/j.cell.2020.02.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId>
            <ArticleId IdType="pmc">PMC7102627</ArticleId>
            <ArticleId IdType="pubmed">32142651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaimes J. A.; Millet J. K.; Whittaker G. R.
Proteolytic cleavage of the SARS-CoV-2 spike protein
and the role of the novel S1/S2 Site. iScience
2020, 23, 101212.10.1016/j.isci.2020.101212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.isci.2020.101212</ArticleId>
            <ArticleId IdType="pmc">PMC7255728</ArticleId>
            <ArticleId IdType="pubmed">32512386</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
